<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200515047452N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-08-23</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>The efficacy of Etomidate and Propofol in sedation induction of children undergoing gastrointestinal endoscopy</public_title>
      <acronym></acronym>
      <scientific_title>Comparison the efficacy of Etomidate and Propofol in sedation induction in children undergoing upper gastrointestinal endoscopy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-08-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/49943</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple randomization is assigned to a number from one to 90, respectively, to those who were eligible for the study. Then, without prior awareness, even numbers are allocated in the intervention group and odd numbers in the control group, Blinding description: This study was conducted double-blinded: the patients (children) and the evaluator (analyzer) were not aware of the course of the intervention. Intervention under the same conditions as P and E the intervention groups. after dilution 1 mg/kg Propofol and 0.1 mg/kg Etomidate were same as color, smell and volume.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Complications of sedation during endoscopic procedure.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: In this group, Propofol 1%, 1 mg / kg will be injected intravenously immediately before endoscopy. Intervention 2: Intervention group 2: In this group, Etomidate 0.2%,  0.1 mg/kg will be injected intravenously immediately before endoscopy.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Demographic information of intervention groups;
Complications of sedation in intervention groups

When:
At the end of the study

To whom:
All of them have aimed secondary research.

Conditions:
For secondary research.

Where to obtain:
Mofid Children's Hospital affiliated to Shahid Beheshti University of Medical Sciences-anesthesia research center-Dr. Tahereh Chavoshi

How to obtain:
Requesting by email.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Tahereh Chavoshi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>7th Floor; Building No.2; Shahid Beheshti University of Medical Sciences; Arabi Ave; Daneshjoo Blvd; Velenjak</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>19839-63113</zip>
        <telephone>+98 21 2243 9781</telephone>
        <email>t.chavoshi@yahoo.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Tahereh Chavoshi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>7th Floor; Building No.2; Shahid Beheshti University of Medical Sciences; Arabi Ave; Daneshjoo Blvd; Velenjak</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>19839-63113</zip>
        <telephone>+98 21 2243 9781</telephone>
        <email>t.chavoshi@yahoo.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Children at the age of 1 to 15 years old
Candidate for upper gastrointestinal tract endoscopic procedure
Class I &amp; II</inclusion_criteria>
      <agemin>1 year</agemin>
      <agemax>15 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of drug allergy to Propofol or Etomidite
Kidney disease
Liver disease
Adrenal disease
Severe pneumonia
ICU hospitalization
History of Postoperative nausea and vomiting
G6PD deficiency</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>T81</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Complications of procedures, not elsewhere classified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: In this group, Propofol 1%, 1 mg / kg will be injected intravenously immediately before endoscopy.</i_keyword>
      <i_keyword>Intervention group 2: In this group, Etomidate 0.2%,  0.1 mg/kg will be injected intravenously immediately before endoscopy.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Blood pressure changes. Timepoint: Immediately before anesthesia and after anesthesia (first minute, 5th minute, 10th minute and 15th minute) will be monitored and recorded. Method of measurement: Blood pressure monitorinng.</prim_outcome>
      <prim_outcome>Apnea (the cessation of breathing for 10 secounds). Timepoint: Continuously. Method of measurement: Observation of respiratory movements and pulse oximeter changes.</prim_outcome>
      <prim_outcome>Frequency of Laryngospasm (closure of the vocal cords and lack of air transfer to the lungs and vice versa). Timepoint: Continuously. Method of measurement: Observation.</prim_outcome>
      <prim_outcome>Duration of Laryngospasm (during time from closure of the vocal cords and lack of air transfer to the lungs and vice versa to bag valve mask ventilation). Timepoint: Continuously. Method of measurement: Cornometer.</prim_outcome>
      <prim_outcome>Duration of Anesthesia recovery. Timepoint: once at recovery room. Method of measurement: Cornometer.</prim_outcome>
      <prim_outcome>Nausea and vomiting. Timepoint: Continuously. Method of measurement: Observation.</prim_outcome>
      <prim_outcome>Agitation. Timepoint: After anesthesia (first minute, 5th minute, 10th minute and 15th minute) will be monitored and recorded. Method of measurement: Sedation Scale for Agitation score,.</prim_outcome>
      <prim_outcome>Heart rate changes. Timepoint: Immediately before anesthesia and after anesthesia (first minute, 5th minute, 10th minute and 15th minute) will be monitored and recorded. Method of measurement: puls oximetry.</prim_outcome>
      <prim_outcome>Respiratory rate changes. Timepoint: Immediately before anesthesia and after anesthesia (first minute, 5th minute, 10th minute and 15th minute) will be monitored and recorded. Method of measurement: Chest movement per minute.</prim_outcome>
      <prim_outcome>Awakening from sedation. Timepoint: Getting to recovey unit until obey the commands and communication with parents. Method of measurement: Observation.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-05-11</approval_date>
        <contact_name>Ethics committee of Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>7th Floor; Building No.2; Shahid Beheshti University of Medical Sciences; Arabi Ave; Daneshjoo Blvd; Velenjak Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
